The COVID-19 pandemic has put a spotlight on the need for effective tools for quality measurement and reporting initiatives. Both Medicare and Medicaid are being impacted by changes to the way care is delivered and data is captured.

Dr. Brian Patel, Chief of Emergency Medicine at Sturdy Memorial Hospital, and Deborah Jean Parsons, Ph.D. Director of Integrated Care at Aspire Health Alliance, share actionable best practices for developing better community partnerships to support patients struggling with complex comorbid physical, behavioral, mental, and SDOH challenges.

Novartis AG secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of the medicine’s value, according to a company executive and a Reuters review of public filings.

CVS Health Corp. and the drugstore chain’s Omnicare unit were sued by the U.S. government, which accused them of fraudulently billing Medicare and other programs for drugs for older and disabled people without valid prescriptions.

A new study conducted by the Pacific Research Institute (PRI) found that wider adoption of biosimilars in the United States would create significant savings to state Medicaid programs and consumers with commercial insurance.

Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.

The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.

Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.

Medical treatment would be more widely available to opioid abusers under a rare bipartisan measure aimed at tackling the U.S. addiction crisis expected to be signed into law by President Trump.

AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.